Helius Medical Technologies announced today that its wholly owned subsidiary, NeuroHabilitation Corporation, has been assessed by Lloyd’s Register Quality Assurance Limited and recommended for ISO 13485 certification for its Portable Neuromodulation Stimulator.
through the tongue.
Helius Medical Technologies, Inc. (TSX:HSM, OTCQB:HSDT) (“Helius” or the “Company”) announced today that its wholly owned subsidiary, NeuroHabilitation Corporation, has been assessed by Lloyd’s Register Quality Assurance Limited (LRQA) and recommended for ISO 13485 certification for its Portable Neuromodulation Stimulator (PoNS™), an investigational non-invasive device designed to deliver neurostimulation
through the tongue. LRQA, an independent certifying agency, concluded that the company complies with the requirements of ISO 13485 for an integrated quality management system for medical devices across all functions of the business, from design and development to manufacturing and distribution.
Achievement of ISO 13485 certification constitutes an important
regulatory milestone in the commercialization process for the company’s
products. The ISO 13485 standard specifies requirements for a quality
management system where an organization needs to demonstrate its ability
to provide medical devices that consistently meet customer requirements
and regulatory requirements applicable to medical devices.
“The ISO 13485 certification illustrates our commitment to quality, our
ability to reach milestones required for product commercialization and,
above all, our dedication to seeing PoNS™ Therapy through to approval,”
said Helius CFO/COO, Joyce LaViscount.
With this certification, Helius will be proceeding with a CE Mark
application in Europe, a Health Canada Medical Device License
Application for Canada and a Therapeutic Goods Association application
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on
neurological wellness. Helius seeks to develop, license and acquire
unique and non-invasive platform technologies that amplify the brain’s
ability to heal itself. Helius intends to file for FDA clearance for the
PoNS™ device. For more information, please visit www.heliusmedical.com.
About PoNS™ Therapy
The PoNS™ device is an investigational non-invasive method to deliver
neurostimulation through the tongue. PoNS™ Therapy combines the use of
the investigational device with physiotherapy and is currently being
evaluated in a pivotal, multicenter, clinical trial for the treatment of
balance disorder in subjects with mild to moderate Traumatic Brain
Injury (TBI). The PoNS ™ Therapy is also being evaluated in the
treatment of symptoms related to other neurologic diseases including
Multiple Sclerosis and Cerebral Palsy.
The Toronto Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical
facts and constitute forward-looking statements or forward-looking
information within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws (“forward-looking
All statements other than statements of historical fact included in this
news release are forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include, among others,
statements regarding ongoing or planned clinical research, expected
future development timelines, regulatory approvals, business initiatives
and objectives and use of proceeds from financings or other business
Forward-looking statements are often identified by terms such as “will”,
“may”, “should”, “anticipate”, “expects” and similar expressions.
There can be no assurance that such statements will prove to be accurate
and actual results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include the failure of the Company to achieve its business objectives
and other risks detailed from time to time in the filings made by the
Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any
forward-looking statements may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from those
predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the control
of the Company. The reader is cautioned not to place undue reliance on
any forward-looking statement. Such information, although considered
reasonable by management at the time of preparation, may prove to be
incorrect and actual results may differ materially from those
anticipated. Forward-looking statements contained in this news release
are expressly qualified by this cautionary statement. Risks and
uncertainties about the Company’s business are more fully discussed in
the Company’s disclosure materials, including the short form prospectus
filed in connection with the Offering, its Annual Report on Form 10-K
filed with the United States Securities and Exchange Commission and the
Canadian securities regulators and which can be obtained from either at www.sec.gov